{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:53:40Z","timestamp":1793044420506,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Open Access funding enabled and organized by Projekt DEAL."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40259-024-00678-x","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T03:17:08Z","timestamp":1727666228000},"page":"845-854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Biochemical Amenability in Fabry Patients Under Chaperone Therapy\u2014How and When to Test?"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8409-2886","authenticated-orcid":false,"given":"Malte","family":"Lenders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise Raphaela","family":"Menke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"678_CR1","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285:2743\u20139.","journal-title":"JAMA"},{"key":"678_CR2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","volume":"8","author":"CM Eng","year":"2006","unstructured":"Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ, Bultas J, Lee P, Sims K, Brodie SE, Pastores GM, Strotmann JM, Wilcox WR. Fabry disease: guidelines for the evaluation and management of multiorgan system involvement. Genet Med. 2006;8:539\u201348.","journal-title":"Genet Med"},{"key":"678_CR3","doi-asserted-by":"crossref","unstructured":"Wallace EL, Goker-Alpan O, Wilcox WR, Holida M, Bernat J, Longo N, Linhart A, Hughes DA, Hopkin RJ, T\u00f8ndel C, Langeveld M, Giraldo P, Pisani A, Germain DP, Mehta A, Deegan PB, Molnar MJ, Ortiz D, Jovanovic A, Muriello M, Barshop BA, Kimonis V, Vujkovac B, Nowak A, Geberhiwot T, Kantola I, Knoll J, Waldek S, Nedd K, Karaa A, Brill-Almon E, Alon S, Chertkoff R, Rocco R, Sakov A, Warnock DG. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study. J Med Genet. 2023:jmg-2023-109445.","DOI":"10.1136\/jmg-2023-109445"},{"key":"678_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezgu F, Amartino H, Bratkovic D, Feldt-Rasmussen U, Nedd K, Sharaf El Din U, Lourenco CM, Banikazemi M, Charrow J, Dasouki M, Finegold D, Giraldo P, Goker-Alpan O, Longo N, Scott CR, Torra R, Tuffaha A, Jovanovic A, Waldek S, Packman S, Ludington E, Viereck C, Kirk J, Yu J, Benjamin ER, Johnson F, Lockhart DJ, Skuban N, Castelli J, Barth J, Barlow C, Schiffmann R. Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat. N Engl J Med. 2016;375:545\u201355.","journal-title":"N Engl J Med"},{"key":"678_CR5","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/gim.2016.122","volume":"19","author":"ER Benjamin","year":"2017","unstructured":"Benjamin ER, Della Valle MC, Wu X, Katz E, Pruthi F, Bond S, Bronfin B, Williams H, Yu J, Bichet DG, Germain DP, Giugliani R, Hughes D, Schiffmann R, Wilcox WR, Desnick RJ, Kirk J, Barth J, Barlow C, Valenzano KJ, Castelli J, Lockhart DJ. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017;19:430\u20138.","journal-title":"Genet Med"},{"key":"678_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","volume":"79","author":"EH McCafferty","year":"2019","unstructured":"McCafferty EH, Scott LJ. Migalastat: a review in Fabry disease. Drugs. 2019;79:543\u201354.","journal-title":"Drugs"},{"key":"678_CR7","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1093\/ehjcvp\/pvab025","volume":"8","author":"M Lenders","year":"2022","unstructured":"Lenders M, Nordbeck P, Kurschat C, Eveslage M, Karabul N, Kaufeld J, Hennermann JB, Patten M, Cybulla M, M\u00fcntze J, \u00dc\u00e7eyler N, Liu D, Das AM, Sommer C, Pogoda C, Reiermann S, Duning T, Gaedeke J, von Cossel K, Blaschke D, Brand SM, Mann WA, Kampmann C, Muschol N, Canaan-K\u00fchl S, Brand E. Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS). Eur Heart J Cardiovasc Pharmacother. 2022;8:272\u201381.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"678_CR8","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1136\/jmg-2022-108669","volume":"60","author":"DA Hughes","year":"2023","unstructured":"Hughes DA, Bichet DG, Giugliani R, Hopkin RJ, Krusinska E, Nicholls K, Olivotto I, Feldt-Rasmussen U, Sakai N, Skuban N, Sunder-Plassmann G, Torra R, Wilcox WR. Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes. J Med Genet. 2023;60:722\u201331.","journal-title":"J Med Genet"},{"key":"678_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.omtm.2020.08.012","volume":"19","author":"M Lenders","year":"2020","unstructured":"Lenders M, Stappers F, Brand E. In vitro and in vivo amenability to Migalastat in Fabry disease. Mol Ther Methods Clin Dev. 2020;19:24\u201334.","journal-title":"Mol Ther Methods Clin Dev."},{"key":"678_CR10","doi-asserted-by":"publisher","first-page":"1220637","DOI":"10.3389\/fmed.2023.1220637","volume":"10","author":"DG Bichet","year":"2023","unstructured":"Bichet DG, Hopkin RJ, Aguiar P, Allam SR, Chien YH, Giugliani R, Kallish S, Kineen S, Lidove O, Niu DM, Olivotto I, Politei J, Rakoski P, Torra R, T\u00f8ndel C, Hughes DA. Consensus recommendations for the treatment and management of patients with Fabry disease on migalastat: a modified Delphi study. Front Med (Lausanne). 2023;10:1220637.","journal-title":"Front Med (Lausanne)."},{"key":"678_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ymgme.2020.07.007","volume":"131","author":"U Feldt-Rasmussen","year":"2020","unstructured":"Feldt-Rasmussen U, Hughes D, Sunder-Plassmann G, Shankar S, Nedd K, Olivotto I, Ortiz D, Ohashi T, Hamazaki T, Skuban N, Yu J, Barth JA, Nicholls K. Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Mol Genet Metab. 2020;131:219\u201328.","journal-title":"Mol Genet Metab"},{"key":"678_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/4801","volume":"5","author":"JQ Fan","year":"1999","unstructured":"Fan JQ, Ishii S, Asano N, Suzuki Y. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med. 1999;5:112\u20135.","journal-title":"Nat Med"},{"key":"678_CR13","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1046\/j.1432-1327.2000.01457.x","volume":"267","author":"N Asano","year":"2000","unstructured":"Asano N, Ishii S, Kizu H, Ikeda K, Yasuda K, Kato A, Martin OR, Fan JQ. In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur J Biochem. 2000;267:4179\u201386.","journal-title":"Eur J Biochem"},{"key":"678_CR14","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","volume":"66","author":"GE Linthorst","year":"2004","unstructured":"Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int. 2004;66:1589\u201395.","journal-title":"Kidney Int"},{"key":"678_CR15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1681\/ASN.2014121226","volume":"27","author":"M Lenders","year":"2016","unstructured":"Lenders M, Stypmann J, Duning T, Schmitz B, Brand SM, Brand E. Serum-mediated inhibition of enzyme replacement therapy in Fabry disease. J Am Soc Nephrol. 2016;27:256\u201364.","journal-title":"J Am Soc Nephrol"},{"key":"678_CR16","doi-asserted-by":"publisher","first-page":"1266082","DOI":"10.3389\/fimmu.2023.1266082","volume":"14","author":"M Lenders","year":"2023","unstructured":"Lenders M, Feidicker LM, Brand SM, Brand E. Characterization of pre-existing anti-PEG and anti-AGAL antibodies towards PRX-102 in patients with Fabry disease. Front Immunol. 2023;14:1266082.","journal-title":"Front Immunol"},{"key":"678_CR17","first-page":"157","volume":"81","author":"RJ Desnick","year":"1973","unstructured":"Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW, Krivit W. Fabry\u2019s disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med. 1973;81:157\u201371.","journal-title":"J Lab Clin Med"},{"issue":"112","key":"678_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0009-8981(81)90384-3","volume":"5","author":"JS Mayes","year":"1981","unstructured":"Mayes JS, Scheerer JB, Sifers RN, Donaldson ML. Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry\u2019s disease. Clin Chim Acta. 1981;5(112):247\u201351.","journal-title":"Clin Chim Acta"},{"key":"678_CR19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1096-7192(03)00136-7","volume":"80","author":"R Froissart","year":"2003","unstructured":"Froissart R, Guffon N, Vanier MT, Desnick RJ, Maire I. Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab. 2003;80:307\u201314.","journal-title":"Mol Genet Metab"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00678-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-024-00678-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00678-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T12:10:13Z","timestamp":1736597413000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-024-00678-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["678"],"URL":"https:\/\/doi.org\/10.1007\/s40259-024-00678-x","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"assertion":[{"value":"19 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. There was no specific funding for conducting this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M.L. received research grants and\/or speaker honoraria from Amicus Therapeutics, Sanofi, Chiesi, Sumitomo Pharma, and Takeda. E.B. received research grants and\/or speaker honoraria from Amicus Therapeutics, Sanofi, Chiesi, Takeda, and Eleva. E.R.M. has nothing to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The original contributions presented in the study are included in the article\/Supplementary Material; further inquiries can be directed to the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"All investigations were performed after approval by the Medical Association of Westphalian-Lippe and the Ethics Committee of the Medical Faculty of the University of Muenster (project no. 2011-347-f, date of report 7 July 2011) and in accordance with the Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all included patients for analysis and publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the article by participating in the conception and design (M.L.), acquisition of data (M.L., E.R.M., and E.B.) or formal analysis (M.L. and E.R.M.) and interpretation of data (M.L., E.R.M., and E.B.), drafting the article (M.L. and E.R.M.) or revising it critically for important intellectual content (E.B.). All authors read and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}